Article:The impacts of H. pylori virulence factors on the development of gastroduodenal diseases (6131906)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q58752500. Its title is The impacts of H. pylori virulence factors on the development of gastroduodenal diseases and the publication date was 2018-09-11. The initial author is Wei-Lun Chang.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: Journal of Biomedical Science

The impacts of H. pylori virulence factors on the development of gastroduodenal diseases

  • Wei-Lun Chang
  • Yi-Chun Yeh
  • Bor-Shyang Sheu

Publication date (epub): 9/2018

Publication date (pmc-release): 9/2018

Publication date (collection): /2018

Abstract

Although most H. pylori infectors are asymptomatic, some may develop serious disease, such as gastric adenocarcinoma, gastric high-grade B cell lymphoma and peptic ulcer disease. Epidemiological and basic studies have provided evidence that infection with H. pylori carrying specific virulence factors can lead to more severe outcome. The virulence factors that are associated with gastric adenocarcinoma development include the presence, expression intensity and types of cytotoxin-associated gene A (CagA, especially EPIYA-D type and multiple copies of EPIYA-C) and type IV secretion system (CagL polymorphism) responsible for its translocation into the host cells, the genotypes of vacuolating cytotoxin A (vacA, s1/i1/m1 type), and expression intensity of blood group antigen binding adhesin (BabA, low-producer or chimeric with BabB). The presence of CagA is also related to gastric high-grade B cell lymphoma occurrence. Peptic ulcer disease is closely associated with cagA-genopositive, vacA s1/m1 genotype, babA2-genopositive (encodes BabA protein), presence of duodenal ulcer promoting gene cluster (dupA cluster) and induced by contact with epithelium gene A1 (iceA1), and expression status of outer inflammatory protein (OipA). The prevalence of these virulence factors is diverse among H. pylori isolated from different geographic areas and ethnic groups, which may explain the differences in disease incidences. For example, in East Asia where gastric cancer incidence is highest worldwide, almost all H. pylori isolates were cagA genopositive, vacA s1/i1/m1 and BabA-expressing. Therefore, selection of appropriate virulence markers and testing methods are important when using them to determine risk of diseases. This review summarizes the evidences of H. pylori virulence factors in relation with gastroduodenal diseases and discusses the geographic differences and appropriate methods of analyzing these virulence markers.

Paper

Background

H. pylori infection is highly prevalent affecting half of the world’s population. Once infected, H. pylori can be a lifelong infection in the host unless eradicated. Nevertheless, about 85% of the infected patients only have mild asymptomatic gastritis, while 15% of patients can develop to have peptic ulcer disease (PUD), and less than 1% can develop to have gastric cancer [[1]].

The diverse clinical presentation of H. pylori infection is a result of interaction between bacterial virulence (e.g. CagA, VacA, BabA), host genetic (e.g. IL-1β, IL-10, TNF-α), and environmental factors (e.g. diet, smoke). The virulence factors of H. pylori can be categorized to be related with 3 major pathogenic processes, including colonization, immune escape and disease induction (Table 1). The virulence factors responsible for establishing colonization include urease, flagella, chemotaxis system, and adhesins [[2], [3]]. Knocking out the urease, flagella or chemotaxis genes all leads to a failure of H. pylori to establish colonization [[3]]. With increasing antibiotic resistance, these virulence factors provide alternative drug or vaccine targets for H. pylori eradication and prevention [[4]]. The virulence factors responsible for immune escape help H. pylori escape from host immune clearance and allow its persistence in the human stomach [[5]]. This review focused on the virulence factors causing more serious clinical outcomes.Table 1

The 3 categories of H. pylori virulence factors and their functions

The three categories of virulence factors Biological functions or associated diseases
Colonization Biological functions
Urease  Neutralize gastric acid
Flagella Chemotaxis system  Bacterial movement to epithelial surface & deep gland
Adhesins  Adherence to gastric epithelial cells
 • BabA
 • SabA
 • Lewis antigens
 • OipA
Immune escape Biological functions
 LPS & Flagella  Low immunogenicity Molecular mimicry Induce anti-inflammatory response
 CagA & T4SS  Suppress phagocytosis Decrease antimicrobial peptide Induce tolerogenic dendritic cell Block effector T cell response
 VacA  Suppress phagocytosis Induce tolerogenic dendritic cell Block effector T cell response
 Gamma-glutamyl transpeptidase  Induce tolerogenic dendritic cell Block effector T cell response
 Cholesterol-α-glucosyltransferase  Suppress phagocytosis
 Catalase Superoxide dismutase  Suppress and ROS & NO
 Arginase  Suppress ROS & NO Block effector T cell response
Disease induction Associated diseases
 CagA & T4SS  Gastric adenocarcinoma, MALToma & PUD
 VacA  Gastric adenocarcinoma & PUD
 BabA  Gastric adenocarcinoma & PUD
 HtrA  Gastric adenocarcinoma
 DupA  Duodenal ulcer
 IceA  PUD
 OipA  PUD

LPS Lipopolysaccharide, T4SS type IV secretion system, ROS reactive oxygen species, NO nitric oxide, PUD peptic ulcer disease

Virulence factors associated with gastric adenocarcinoma

Gastric adenocarcinoma is the most deadly disease cause by H. pylori. The virulence factors that are associated with development of gastric adenocarcinoma are summarized in Table 2.Table 2

The H. pylori virulence factors associated with gastric adenocarcinoma

Region Virulence factor (High risk marker) Odds ratio Analytic method Reference
East Asia CagL Y58E59 (vs. non-Y58E59) 4.6 DNA sequencing [[25]]
Bab AB BA recombination (vs. others) 6.2 PCR [[44]]
Middle Asia vacA i1 (vs. i2) 10.9 PCR [[34]]
Middle East vacA s1 (vs. s2) 4.0 PCR [[36]]
vacA m1 (vs. m2) 2.5 PCR [[36]]
vacA s1/m1 (vs. s2/m2) 5.3 PCR [[36]]
vacA i1 (vs. i2) 15.0 PCR [[36]]
Asia EPIYA-D motif of CagA (vs. EPIYA-C) 1.9 DNA sequencing [[30]]
Western countries Positive serum anti-CagA Ab 2.0 Serum ELISA [[19]]
cagA+ (vs. cagA-) 2.4 PCR or Immunoblot [[20]]
≥ 2 copies of EPIYA-C motifs of CagA (vs. 1 copy) 3.3 DNA sequencing [[30]]
Western EPIYA-B motif of CagA (vs. EPIYT-B) 3.0 DNA sequencing [[29]]
vacA s1 (vs. s2) 5.3 PCR [[20]]
vacA m1 (vs. m2) 2.5 PCR [[20]]
vacA s1/m1 (vs. s2/m2) 4.4 PCR [[20]]
BabA-L (vs. BabA-negative) 33.9 Immunoblot [[46]]
BabA-H (vs. BabA-negative) 18.2 Immunoblot [[46]]
oipA “on” (vs. oipA “off”) 2.4 DNA sequencing or immunoblot [[74]]

PCR Polymerase chain reaction

Cytotoxin-associated gene a (CagA) & type IV secretion system (T4SS)

CagA is a well-recognized oncoprotein which is injected into host cells via a pilus structure called type IV secretion system (T4SS) [[6]]. Successful pilus formation and CagA translocation relies on the binding between CagL on the tip of T4SS and integrin α5β1 receptor on the host cell [[7]]. The gene locus that encodes CagA and the T4SS is called cag pathogenicity island (cag PAI). After being injected into host cells, CagA alters intracellular signal transduction pathways that facilitates malignant transformation of gastric epithelial cells or activates Lgr5-positive stem cells [[8], [9]]. Importantly, transgenic mice overexpressing phosphorylation-competent CagA developed gastrointestinal adenocarcinoma, myeloid leukemia and B cell lymphoma, while phosphorylation-resistant CagA could not confer the same pathological changes [[10]]. These data provided direct evidence that CagA is an oncoprotein and the need of phosphorylation in conferring oncogenesis.

In addition to the above cellular changes, CagA and T4SS also increase gastric inflammation via NFκB signaling and increased IL-8 secretion [[11], [12]], which predispose to genetic instability and carcinogenesis. CagA can also cause epigenetic changes, such as DNA promoter or histone hypermethylation, which in turn leads to downregulation of tumor suppressor genes (e.g. MGMT) or microRNAs (e.g. let-7) [[13], [14]]. Alternatively, CagA can attenuate tumor suppressing microRNA expression (e.g. miR-320a, miR-4496) via unknown mechanisms [[15], [16]]. Therefore, CagA and T4SS can contribute to gastric carcinogenesis via multiple mechanisms.

In concordance with the above-mentioned in vitro and in vivo evidences, several epidemiologic studies also support infection with CagA-positive H. pylori can increase the gastric cancer risk, especially for the non-cardiac location. Most of these studies just tested the serum antibodies against CagA protein to define the status of a CagA-positive H. pylori infection [[17][19]]. Meta-analyses of case-control studies showed CagA-seropositive is associated with 2-fold risk of distal gastric cancer among H. pylori infectors [[19]], while cagA-genopositive is associated with 2.1–2.4 fold risk of gastric cancer [[20]]. A cohort study with long-term follow-up also demonstrated that infection with cagA-genopositive strain was associated with greater risk of progression of gastric precancerous lesion (OR = 2.28). However, in East Asia, where nearly all H. pylori strains possess cagA gene [[21]], presence of serum anti-CagA antibody or cagA gene may not be sensitive enough [[22]], and CagA subtyping is suggested to identify high risk infectors (Table 2).

Accordingly, the risk of gastric cancer in CagA-positive H. pylori infector can be further stratified by CagA expression level [[23], [24]], the amount of translocation into host cell [[25], [26]] and its biological activity [[27][29]]. CagA expression level is higher with the presence of genetic AATAAGATA motif upstream of the translation-starting site, which was associated with greater risk of advanced gastric precancerous lesion [[23], [24]]. The amount of CagA translocation is greater in strains harboring an amino acid sequence polymorphism (Y58E59) in the CagL of T4SS, which increases its binding affinity with integrin receptor α5β1 on the gastric epithelial cell [[26]]. Accordingly, gastric cancer risk was increased by 4.6-fold in patients infected by CagL-Y58E59 strain compared with those infected by non-Y58E59 strain [[25]].

The biological activity of CagA protein is determined by the types and numbers of the EPIYA motifs on its C-terminal region. There are four types of EPIYA motifs based on their distinct conserved flanking sequences, namely EPIYA-A, -B, -C and -D. H. pylori isolates from East Asia where gastric cancer incidence is highest often contains EPIYA A-B-D motif, whereas isolates from Western countries often contains EPIYA A-B-C motif. The A-B-D motif has stronger Src homology 2 phosphatase (SHP-2) binding affinity than the A-B-C motif [[27]]. A meta-analysis showed 1 EPIYA-D motif was associated with 1.91-fold gastric cancer risk in Asia, compared with 1 EPIYA-C motif [[30]]. In Western countries, strains harboring multiple EPIYA-C motifs (A-B-C-C or A-B-C-C-C) have higher phosphorylation capacity, SHP-2 binding affinity, and confer higher gastric cancer risk (OR = 3.28) compared with only 1 EPIYA-C motif [[30]]. Notably, a higher CagA phosphorylation ability was associated with increased risk of gastric precancerous lesions in Taiwan [[31]]. In addition, amino acid sequence polymorphism within the Western EPIYA-B motif also influences CagA activity, as strains harboring EPIYT-B motif have attenuated ability of inducing hummingbird phenotype and IL-8 in gastric epithelial cells and confer less gastric cancer risk than strains harboring EPIYA-B motifs [[29]]. Interestingly, EPIYT-B motif was associated with higher duodenal ulcer risk [[29]].

Vacuolating cytotoxin a (VacA)

VacA was named for its ability to induce vacuole formation in eukaryotic cells. The difference in vacuolating abilities are determined by the variations in the three regions of the vacA gene — the signal (s1 and s2), intermediate (i1 and i2) and middle regions (m1 and m2). A combination of different sequences in the 3 regions leads to multiple alleles and determines the vacuolating activity. Vacuolating activity is high in s1/m1 genotypes, intermediate in s1/m2 genotypes, and absent in s2/m2 genotypes [[32]]. In clinical isolates, only s1/m2 strain varies in i-type; s1/m1 and s2/m2 strains are exclusively i1 and i2, respectively [[33]]. The i-type determines vacuolating activity among the s1/m2 strains [[33]]. Even though the physiologic role of vacuolation is unclear, higher vacuolation activity was linked with more severe clinical outcomes of the infection.

Meta-analysis showed individuals infected with H. pylori harboring vacA s1 or m1 has an increased risk of gastric cancer in Western populations (OR = 2.50–5.32, Table 2) [[20]]. Moreover, vacA i1 type H. pylori infection is associated with higher gastric cancer risk in the Middle Asia and Middle East area (OR = 10.9–15.0) [[34]]. However, similar to CagA, the high prevalence of vacA s1/i1/m1 genotype in the East Asian and Southeast Asian population dampens its application as a disease determinant in these areas [[35]].

Interestingly, the s1/i1/m1 type of vacA is often linked with genopositive cagA [[36]]. Therefore, neither of the virulence markers can be considered an independent factor for disease outcome [[37]]. In fact, when multiple virulence factors are present, the risk of severe clinical outcome is greater. For example, in a long-term follow-up cohort, infection with strains that are simultaneously cagA-genopositive and vacA s1/m1 was associated 4.8-fold risk of progression of gastric precancerous lesions compared to those infected with cagA-negative/vacA s2/m2 strains, which was higher than each of the virulence factors considered alone (OR = 2.28–3.38) [[38]].

Blood group antigen binding adhesin (BabA)

BabA encoded by babA2 gene is a major adhesin on the outer membrane of H. pylori, which recognizes Lewis b (Leb) blood group antigens on the host cells and determines H. pylori colonization density [[39], [40]]. Two other paralogs of BabA had been found — the BabB and BabC, encoded by babB and babC gene, respectively. The sequence of the 3 bab genes was similar in the 5′ and 3′ region particularly between babA and babB, but the middle region was diverse and likely mediates the binding function. Thus, only BabA has Leb antigen binding ability [[41], [42]]. The BabA protein expression is mainly regulated by the recombination between babA and babB gene, which forms chimeric proteins (BabA/B or BabB/A) [[41], [43], [44]]. For example, intra-genomic recombination with babB brings variable number of cytosine-thiamidine (CT) dinucleotide to the 5′-region of the babA sequence, leading to phase variation and affects the expression of BabA [[43]]. Other mechanisms that regulate BabA expression includes mutation in the coding region of the babA2 gene, or the presence of 4 additional adenines (poly[A] nucleotides) within the − 10 to − 35 region of the babA2 promoter, which diminishes the strength of the promoter [[43]].

Therefore, using a single pair of PCR primers to determine babA2 genopositivity may not reflect the actual expression status of BabA. This may explain the conflicting results of studies exploring the correlation between babA2 genopositivity and gastric cancer [[45]]. Fujimoto et al. determined BabA expression level by immunoblotting and classified H. pylori into BabA high producers (BabA-H) with Leb binding activity, BabA low producers (BabA-L) without Leb binding activity, and BabA-negative strain (babA2-genonegative) [[46]]. Notably, infection with BabA-L strains was associated with highest risk of gastric cancer, followed by infection with BabA-H and BabA-negative strains. In Western countries, infection with BabA-L and BabA-H strain are associated with 54.8-fold and 19.8-fold risk of gastric cancer compared to BabA-negative infectors. Moreover, BabA-L strain infectors had highest gastric H. pylori colonization density, neutrophil infiltration, and mucosal atrophy. However, since all H. pylori isolates from East Asia are either BabA-H or BabA-L, the categorization is not sensitive enough to risk stratify infectors in this area.

In Taiwan, we explored babA and babB recombination using multiple pairs of PCR primers. Four types of babA and babB recombination can be found — the A B genotype without recombination, AB B with babB inserted into babA, A BA with babA inserted into babB, and AB BA with both of the recombination [[44]]. The isolates from gastric cancer patients had a higher rate of AB BA genotype than those from non-cancer patients (40.0% vs. 9.7%, OR = 6.2, p < 0.05). Interestingly, isolates with AB BA genotype had lower BabA expression level than isolates with A B genotype [[44]]. Therefore, although babA2-genonegative strain was associated with lowest gastric cancer risk [[46]], in babA2-genopositive strain, a lower BabA expression level seemed to be associated higher gastric cancer risk [[44], [46]]. These data suggest multiple pairs of PCR primers should be used to reflect actual BabA status and determine the risk of gastric cancer, especially in East Asia where nearly 100% H. pylori are babA2-genopositive [[40], [46]].

Notably, H. pylori that simultaneously expresses multiple virulence factors is associated with an even higher risk of severe clinical outcomes. A case-control study showed Infection with strains “triple-positive” for cagA, vacAs1 and babA2 genes significantly correlates to the development of peptic ulcer (p < 0.0001) and adenocarcinoma (p = 0.014) and discriminated adverse disease outcome better than did the dual-positive (cagA and vacA1) classification [[47]].

High temperature requirement a (HtrA)

H. pylori can secrete proteases as well as induce the expression of host proteases to cleave extracellular matrix and intercellular junctional proteins. Disruption of junctional protein is particularly important for H. pylori to exploit the host receptors located on the basolateral side of the cell membrane, such as integrin [[48]]. The serine protease and chaperone HtrA is most studied protease expressed by H. pylori. Intracellular HtrA acts as chaperone that refold and degrade misfolded proteins. Thus, HtrA is important for bacterial survival under stressful conditions, such as extreme temperature, pH or salt concentration [[49]]. All clinical H. pylori isolates possesses htrA gene and suppression of HtrA proteolytic activity is sufficient to kill H. pylori [[50]]. Therefore, HtrA is a promising target for anti-H. pylori therapy. In addition to the essential role in H. pylori survival, secreted HtrA can cleave E-cadherin and fibronectin [[51]]. E-cadherin cleavage disrupts cell junctions which exposes basolateral integrin receptors for binding by the H. pylori T4SS, as well as induces epithelial-mesenchymal transition. Since fibronectin has integrin binding motif — RGD, its proteolysis may release integrin receptors on the gastric epithelial cells to interact with H. pylori T4SS, and subsequently facilitate the translocation of CagA [[7]]. It is novel to assess whether htrA genetic polymorphism is associated with gastric cancer risk, especially in the high gastric cancer incidence area.

Virulence factors associated with gastric B cell lymphoma

Previous studies showed cagA gene was found more frequently (p < 0.05) in the biopsies of gastric high-grade B cell lymphoma (76.7%, 23/30) compared to the gastritis (30.3%, 17/56) and the low-grade lymphoma of the mucosa associated lymphoid tissue (MALToma) cases (37.8%, 14/37) [[52]]. In addition, the prevalence of serum anti-CagA antibody was higher (p < 0.05) in patients with gastric diffuse large B cell lymphoma (75%, 12/16) than those with low-grade MALToma (44.8%, 13/29) and non-ulcer dyspepsia (43.1%, 22/53) [[53]]. These data indicates CagA is associated with development of gastric high-grade B cell lymphoma.

In vitro study showed CagA is able to be translocated into human B lymphocytes via T4SS [[54]]. Once in the cytoplasm, it binds to SHP-2, which stimulates B lymphocyte proliferation and inhibits apoptosis via regulation of intracellular pathways, including activation of endoplasmic reticulum kinases 1 and 2 (ERK 1 and ERK 2) and p38 MAP kinase (MAPK) and increased expression of Bcl-2 and Bcl-xL [[54]]. Clinical study also showed positive correlations between the expression of CagA and phospho-SHP-2 (p-SHP-2), p-ERK, p-p38 MAPK, Bcl-2 and Bcl-xL in gastric MALToma tissue [[55]]. Therefore, CagA may promote gastric low-grade MALToma transformation to high-grade B cell lymphoma via the above pathways.

Recently, the genomes of three H. pylori strains isolated from MALToma patients were sequenced. Nine genes were identified to be shared by 3 MALToma strains and absent in the reported 5 gastritis/ulcer strains [[56]]. Further investigations are needed to clarify the impact of these genes in gastric lymphomagenesis.

Virulence factors associated with peptic ulcer disease (PUD)

The virulence factors that are associated with development of PUD are summarized in Table 3.Table 3

The H. pylori virulence factors associated with peptic ulcer disease

Region Virulence factor (High risk marker) Odds ratio Analytic method Reference
East Asia ≥ 2 copies of EPIYA-C motifs of CagA increases DU risk (vs. 1 copy) 2.3 DNA sequencing [[30]]
Southeast Asia cagA-genopositive 2.8 PCR [[58]]
vacA m1 (vs. m2) 1.5 PCR [[58]]
Middle East vacA s1 (vs. s2) 3.1 PCR [[36]]
vacA m1 (vs. m2) 1.8 PCR [[36]]
Asia dupA-genopositive increases DU risk 1.6 PCR [[63]]
Western countries cagA+ (vs. cagA-) 1.7 PCR or Immunoblot [[20]]
vacA s1 (vs. s2) 1.7 PCR [[59]]
vacA s1/m1 (vs. s2/m2) 2.0 PCR [[20]]
babA2-genopositive 2.1 PCR [[45]]
BabA-L (vs. BabA-negative) 54.8 Immunoblot [[46]]
BabA-H (vs. BabA-negative) 19.8 Immunoblot [[46]]
dupA cluster positive increases DU risk 2.1 PCR [[66]]
iceA1-genopositive 1.3 PCR [[70]]
oipA “on” (vs. oipA “off”) 4.0 DNA sequencing or immunoblot [[74]]

PCR Polymerase chain reaction

Cytotoxin-associated gene a (CagA)

In a large meta-analysis including 44 studies and 17,374 patients from both Eastern and Western regions, CagA-seropositive was associated with a 1.69-fold risk of PUD, which was lower than its association with gastric cancer (OR = 2.44) [[20]]. However, due to diverse cagA genoprevalence in the various geographic areas, the methods used to identify high risk population for PUD should be different. In Western and Southeast Asian population, where cagA-genopositive rate is lower, cagA-genopositive is sensitive enough to identify high risk infector for PUD [[57], [58]]. In East Asia, where nearly all H. pylori strains possess cagA gene [[21]], CagA subtyping is suggested to identify high risk infectors. Accordingly, a meta-analysis showed multiple EPIYA-C motifs is associated with 2.3-fold risk of DU compared with 1 EPIYA-C motif in Asian population [[30]].

Vacuolating cytotoxin a (VacA)

As mentioned above, the higher vacuolation activity of strains carrying vacA s1, i1 or m1 genotypes were linked with more severe clinical outcomes than the s2, i2 or m2 genotypes [[20], [32], [33], [36], [58], [59]]. However, similar to cagA genoprevalence, diversity in the prevalence of vacA risky genotypes (s1, i1 and m1) was noted in different geographic regions. Therefore, the use of vacA genotypes to determine PUD risk depends on the prevalence of risky genotypes in each geographic region. In America, Europe, Africa and Middle East where the prevalence of vacA risky genotypes (s1/m1) is lower, individuals infected with vacA s1 or m1 H. pylori strains have an increased risk of PUD compared with those with s2 or m2 strains [[20], [32], [36], [59]]. In Southeast Asia, vacA m1 is associated with increased risk of PUD [[58]]. In East Asia, where most strains are vacA s1/i1/s1 genotype, vacA genotypes cannot differentiate high risk infectors, and other virulence markers should be used [[35]]. The vacA i1 genotype is not associated with risk of PUD in meta-analysis [[34]].

Blood group antigen binding adhesin (BabA)

Both animal and human studies showed that infection by BabA-expressing strains is associated with higher bacterial density and more severe injury in the gastric mucosa [[46], [60]]. A meta-analysis of case-control studies showed that babA2 genopositive is associated with an increased risk of PUD (OR = 2.07) in Western countries, but not in Asian countries [[45]]. As mentioned above, Fujimoto et al. determined BabA expression level by immunoblotting [[46]]. BabA-L (BabA low producers) and BabA-H (BabA high producers) strains were also associated with higher risk of duodenal ulcer than BabA-negative strains in Western countries (OR = 33.9 and 18.2, respectively) [[46]]. However, the underlying mechanisms remained to be elucidated. Despite the positive findings of babA2 genopositive and BabA expression intensity in determining peptic ulcer risk in Western countries, these methods are not sensitive enough to differentiate high risk infector in East Asia. Further studies using multiple sets of babA and babB PCR primers [[44]] are warranted to determine whether babA/B recombination can determine ulcer risk.

Duodenal ulcer promoting gene (DupA)

DupA was initially identified in 2005 and named for its role to increase risk of DU (i.e. duodenal ulcer promoting). The original data showed the presence of dupA gene was associated with increased risk of DU, as well as neutrophil infiltration and IL-8 expression in the antrum [[61]]. In contrast, its presence was also associated with decreased risk of gastric atrophy, intestinal metaplasia, and gastric cancer [[61]]. The data are compatible with the findings that antral predominant gastritis often leads to higher gastric acid secretion and duodenal ulcer formation. Nevertheless, although two meta-analyses found a small increase in DU risk (OR = 1.4) by dupA-genopositive strain [[62], [63]], conflicting results were found [[64], [65]]. In addition, the association was only found in Asian countries, but not in Western countries [[63]]. It has been reported that dupA forms T4SS with vir genes around it (called dupA cluster). H. pylori with complete dupA cluster was associated with 2.1-fold risk of DU than that with incomplete dupA cluster or negative dupA [[66]]. Therefore, merely testing the presence/absence of dupA gene may not reflect the competent function of DupA and analysis of whole dupA cluster may be more accurate to determine DU risk, especially in Western countries [[67]].

Induced by contact with epithelium gene a (IceA)

The iceA gene was originally identified in 1998 when investigating genes “induced by contact of H. pylori with epithelium” [[68]]. Two families of iceA have been found, iceA1 and iceA2. Infection with iceA1-genopositive strain is associated with PUD and increased mucosal levels of IL-8 [[57], [68], [69]]. Meta-analysis showed the presence of iceA1 gene was associated with a small increase of peptic ulcer risk (OR  = 1.28) in Western countries [[70]].

Outer inflammatory protein (OipA)

OipA is an outer membrane protein that functions in adhesion and IL-8 induction. Its functional status (on or off) is regulated by slipped-strand mispairing based on the number of CT dinucleotide repeats in the 5′ region of oipA gene [[71]]. Infection with oipA “on” strain has been linked with higher H. pylori colonization density, neutrophil infiltration and IL-8 levels in the human stomach [[72]]. However, the corresponding receptor for OipA has not been identified.

Previous study showed oipA “on” status was closely linked to cagA-positive, vacA s1/m1, and babA2-positive genotypes [[73]]. Moreover, oipA “on” status was associated with increased risk of DU independent of the other virulence factors [[72]]. A meta-analysis also reported that the oipA “on”, but not “off”, status is significantly associated with an increased risk of PUD (OR = 3.97) and gastric cancer (OR = 2.43), especially in the Western countries [[74]]. Importantly, merely investigating the presence/absence of oipA gene would overlook its functional on/off status and may be unreliable to predict risks of PUD or GC [[74]].

Conclusions

Epidemiological studies had provide evidence that infection with H. pylori carrying specific virulence factors is associated with increased risk of serious clinical outcomes. To identify infectors who are at high risk of serious clinical outcomes, one should select appropriate virulence factors and testing methods according to the epidemiological data of each geographic area and ethnic group.

References

  1. MR AmievaEM El-OmarHost-bacterial interactions in helicobacter pylori infectionGastroenterology2008134130632310.1053/j.gastro.2007.11.00918166359
  2. BS SheuHB YangYC YehJJ WuHelicobacter pylori colonization of the human gastric epithelium: a bug's first step is a novel target for usJ Gastroenterol Hepatol2010251263210.1111/j.1440-1746.2009.06141.x20136973
  3. CY KaoBS SheuJJ WuHelicobacter pylori infection: an overview of bacterial virulence factors and pathogenesisBiom J20163911423
  4. R MenardIC SchoenhofenL TaoA AubryP BouchardCW ReidSmall-molecule inhibitors of the pseudaminic acid biosynthetic pathway: targeting motility as a key bacterial virulence factorAntimicrob Agents Chemother201458127430744010.1128/AAC.03858-1425267679
  5. R Mejias-LuqueM GerhardImmune evasion strategies and persistence of Helicobacter pyloriCurr Top Microbiol Immunol2017400537128124149
  6. S OdenbreitJ PulsB SedlmaierE GerlandW FischerR HaasTranslocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretionScience200028754571497150010.1126/science.287.5457.149710688800
  7. T KwokD ZablerS UrmanM RohdeR HartigS WesslerHelicobacter exploits integrin for type IV secretion and kinase activationNature2007449716486286610.1038/nature0618717943123
  8. S BackertMJ BlaserThe role of CagA in the gastric biology of Helicobacter pyloriCancer Res201676144028403110.1158/0008-5472.CAN-16-168027655809
  9. M SigalME RothenbergCY LoganJY LeeRW HonakerRL CooperHelicobacter pylori activates and expands Lgr5(+) stem cells through direct colonization of the gastric glandsGastroenterology201514871392140410.1053/j.gastro.2015.02.04925725293
  10. N OhnishiH YuasaS TanakaH SawaM MiuraA MatsuiTransgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouseProc Natl Acad Sci U S A200810531003100810.1073/pnas.071118310518192401
  11. A LambXD YangYH TsangJD LiH HigashiM HatakeyamaHelicobacter pylori CagA activates NF-kappaB by targeting TAK1 for TRAF6-mediated Lys 63 ubiquitinationEMBO Rep200910111242124910.1038/embor.2009.21019820695
  12. RJ GorrellJ GuanY XinMA TafreshiML HuttonMG MAA novel NOD1- and CagA-independent pathway of interleukin-8 induction mediated by the Helicobacter pylori type IV secretion systemCell Microbiol201315455457010.1111/cmi.1205523107019
  13. AR SepulvedaY YaoW YanDI ParkJJ KimW GoodingCpG methylation and reduced expression of O6-methylguanine DNA methyltransferase is associated with Helicobacter pylori infectionGastroenterology201013851836184410.1053/j.gastro.2009.12.04220044995
  14. Y HayashiM TsujiiJ WangJ KondoT AkasakaY JinCagA mediates epigenetic regulation to attenuate let-7 expression in Helicobacter pylori-related carcinogenesisGut201362111536154610.1136/gutjnl-2011-30162522936674
  15. DW KangES YangYN NohWC HwangSY JoYA SuhMicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene a (CagA)-induced cancer-initiating potential and chemoresistance by targeting beta-catenin and ATP-binding cassette, subfamily G, member 2J Pathol2017241561462510.1002/path.486628008607
  16. JM NotoMB PiazueloR ChaturvediCA BartelEJ ThatcherA DelgadoStrain-specific suppression of microRNA-320 by carcinogenic Helicobacter pylori promotes expression of the antiapoptotic protein Mcl-1Am J Physiol Gastrointest Liver Physiol201330511G786G79610.1152/ajpgi.00279.201324136787
  17. MJ BlaserGI Perez-PerezH KleanthousTL CoverRM PeekPH ChyouInfection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomachCancer Res19955510211121157743510
  18. J ParsonnetGD FriedmanN OrentreichH VogelmanRisk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infectionGut199740329730110.1136/gut.40.3.2979135515
  19. JQ HuangGF ZhengK SumanacEJ IrvineRH HuntMeta-analysis of the relationship between cagA seropositivity and gastric cancerGastroenterology200312561636164410.1053/j.gastro.2003.08.03314724815
  20. JI MatosHA de SousaR Marcos-PintoM Dinis-RibeiroHelicobacter pylori CagA and VacA genotypes and gastric phenotype: a meta-analysisEur J Gastroenterol Hepatol201325121431144110.1097/MEG.0b013e328364b53e23929249
  21. JC YangTH WangHJ WangCH KuoJT WangWC WangGenetic analysis of the cytotoxin-associated gene and the vacuolating toxin gene in Helicobacter pylori strains isolated from Taiwanese patientsAm J Gastroenterol1997928131613219260797
  22. Z ZhaoY LiS LiuW FuSerum Helicobacter pylori CagA antibody may not be used as a tumor marker for diagnosing gastric cancer in east Asian countriesTumour Biol20143512122171222410.1007/s13277-014-2530-825168369
  23. JT LohCL ShafferMB PiazueloLE BravoMS McClainP CorreaAnalysis of cagA in Helicobacter pylori strains from Colombian populations with contrasting gastric cancer risk reveals a biomarker for disease severityCancer Epidemiol Biomark Prev201120102237224910.1158/1055-9965.EPI-11-0548
  24. RM FerreiraI Pinto-RibeiroX WenR Marcos-PintoM Dinis-RibeiroF CarneiroHelicobacter pylori cagA promoter region sequences influence CagA expression and interleukin 8 secretionJ Infect Dis2016213466967310.1093/infdis/jiv46726401027
  25. YC YehWL ChangHB YangHC ChengJJ WuBS SheuH. Pylori cagL amino acid sequence polymorphism Y58E59 induces a corpus shift of gastric integrin alpha5beta1 related with gastric carcinogenesisMol Carcinog2011501075175910.1002/mc.2075321374738
  26. YC YehHC ChengHB YangWL ChangBS SheuH. pylori CagL-Y58/E59 prime higher integrin alpha5beta1 in adverse pH condition to enhance hypochlorhydria vicious cycle for gastric carcinogenesisPLoS One201388e7273510.1371/journal.pone.007273524009701
  27. H HigashiR TsutsumiA FujitaS YamazakiM AsakaT AzumaBiological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sitesProc Natl Acad Sci U S A20029922144281443310.1073/pnas.22237539912391297
  28. FO Beltran-AnayaTM PobleteA Roman-RomanS ReyesJ de SampedroO Peralta-ZaragozaThe EPIYA-ABCC motif pattern in CagA of Helicobacter pylori is associated with peptic ulcer and gastric cancer in Mexican populationBMC Gastroenterol20141422310.1186/s12876-014-0223-925539656
  29. XS ZhangN TegtmeyerL TraubeS JindalG Perez-PerezH StichtA specific A/T polymorphism in Western tyrosine phosphorylation B-motifs regulates Helicobacter pylori CagA epithelial cell interactionsPLoS Pathog2015112e100462110.1371/journal.ppat.100462125646814
  30. Q LiJ LiuY GongY YuanAssociation of CagA EPIYA-D or EPIYA-C phosphorylation sites with peptic ulcer and gastric cancer risks: a meta-analysisMedicine (Baltimore)20179617e662010.1097/MD.000000000000662028445260
  31. CH ChuangHB YangSM SheuKH HungJJ WuHC ChengHelicobacter pylori with stronger intensity of CagA phosphorylation lead to an increased risk of gastric intestinal metaplasia and cancerBMC Microbiol20111112110.1186/1471-2180-11-12121619658
  32. JC AthertonP CaoRM Peek JrMK TummuruMJ BlaserTL CoverMosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulcerationJ Biol Chem199527030177711777710.1074/jbc.270.30.177717629077
  33. JL RheadDP LetleyM MohammadiN HusseinMA MohagheghiM Eshagh HosseiniA new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancerGastroenterology2007133392693610.1053/j.gastro.2007.06.05617854597
  34. X LiuB HeWC ChoY PanJ ChenH YingA systematic review on the association between the Helicobacter pylori vacA i genotype and gastric diseaseFEBS Open Bio20166540941710.1002/2211-5463.1204627419046
  35. H OgiwaraDY GrahamY YamaokavacA i-region subtypingGastroenterology20081344126710.1053/j.gastro.2007.11.06218395110
  36. M SugimotoMR ZaliY YamaokaThe association of vacA genotypes and Helicobacter pylori-related gastroduodenal diseases in the Middle EastEur J Clin Microbiol Infect Dis200928101227123610.1007/s10096-009-0772-y19551413
  37. JG KustersAH van VlietEJ KuipersPathogenesis of helicobacter pylori infectionClin Microbiol Rev200619344949010.1128/CMR.00054-0516847081
  38. CA GonzalezC FigueiredoCB LicRM FerreiraML PardoJM Ruiz LisoHelicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in SpainAm J Gastroenterol2011106586787410.1038/ajg.2011.121285949
  39. D IlverA ArnqvistJ OgrenIM FrickD KersulyteET IncecikHelicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retaggingScience1998279534937337710.1126/science.279.5349.3739430586
  40. BS SheuSM SheuHB YangAH HuangJJ WuHost gastric Lewis expression determines the bacterial density of Helicobacter pylori in babA2 genopositive infectionGut200352792793210.1136/gut.52.7.92712801945
  41. Y YamaokaRoles of Helicobacter pylori BabA in gastroduodenal pathogenesisWorld J Gastroenterol200814274265427210.3748/wjg.14.426518666312
  42. S AnsariY YamaokaHelicobacter pylori BabA in adaptation for gastric colonizationWorld J Gastroenterol201723234158416910.3748/wjg.v23.i23.415828694656
  43. A BackstromC LundbergD KersulyteDE BergT BorenA ArnqvistMetastability of Helicobacter pylori bab adhesin genes and dynamics in Lewis b antigen bindingProc Natl Acad Sci U S A200410148169231692810.1073/pnas.040481710115557006
  44. SM SheuBS SheuWC ChiangCY KaoHM WuHB YangH pylori clinical isolates have diverse babAB genotype distributions over different topographic sites of stomach with correlation to clinical disease outcomesBMC Microbiol2012128910.1186/1471-2180-12-8922646246
  45. MY ChenCY HeX MengY YuanAssociation of Helicobacter pylori babA2 with peptic ulcer disease and gastric cancerWorld J Gastroenterol201319264242425110.3748/wjg.v19.i26.424223864790
  46. S FujimotoO Olaniyi OjoA ArnqvistJY WuS OdenbreitR HaasHelicobacter pylori BabA expression, gastric mucosal injury, and clinical outcomeClin Gastroenterol Hepatol200751495810.1016/j.cgh.2006.09.01517157077
  47. M GerhardN LehnN NeumayerT BorenR RadW ScheppClinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesinProc Natl Acad Sci U S A19999622127781278310.1073/pnas.96.22.1277810535999
  48. Posselt G, Crabtree JE, Wessler S. Proteolysis in Helicobacter pylori-induced gastric cancer. Toxins (Basel). 2017;9(4):e134.
  49. G HansenR HilgenfeldArchitecture and regulation of HtrA-family proteins involved in protein quality control and stress responseCell Mol Life Sci201370576177510.1007/s00018-012-1076-422806565
  50. N TegtmeyerY MoodleyY YamaokaSR PernitzschV SchmidtFR TraversoCharacterisation of worldwide Helicobacter pylori strains reveals genetic conservation and essentiality of serine protease HtrAMol Microbiol201699592594410.1111/mmi.1327626568477
  51. B HoyM LowerC WeydigG CarraN TegtmeyerT GeppertHelicobacter pylori HtrA is a new secreted virulence factor that cleaves E-cadherin to disrupt intercellular adhesionEMBO Rep2010111079880410.1038/embor.2010.11420814423
  52. H PengR RanaldiTC DissPG IsaacsonI BearziL PanHigh frequency of CagA+ Helicobacter pylori infection in high-grade gastric MALT B-cell lymphomasJ Pathol1998185440941210.1002/(SICI)1096-9896(199808)185:4<409::AID-PATH121>3.0.CO;2-T9828840
  53. JC DelchierD LamarqueM LevyEM TkoubC Copie-BergmanI DeforgesHelicobacter pylori and gastric lymphoma: high seroprevalence of CagA in diffuse large B-cell lymphoma but not in low-grade lymphoma of mucosa-associated lymphoid tissue typeAm J Gastroenterol20019682324232810.1111/j.1572-0241.2001.04036.x11513169
  54. WC LinHF TsaiSH KuoMS WuCW LinP HsuTranslocation of Helicobacter pylori CagA into human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphomaCancer Res201070145740574810.1158/0008-5472.CAN-09-469020587516
  55. SH KuoKH YehLT ChenCW LinPN HsuMS WuHelicobacter pylori CagA translocation is closely associated with the expression of CagA-signaling molecules in low-grade gastric mucosa-associated lymphoid tissue lymphomaAm J Surg Pathol201539676176610.1097/PAS.000000000000043725871616
  56. Wang HC, Cheng FC, Wu MS, Shu HY, Sun HS, Wang YC, et al. Genome sequences of three Helicobacter pylori strains from patients with gastric mucosa-associated lymphoid tissue lymphoma. Genome Announc. 2015;3(2):e00229.
  57. LJ van DoornC FigueiredoR SannaA PlaisierP SchneebergerW de BoerClinical relevance of the cagA, vacA, and iceA status of Helicobacter pyloriGastroenterology19981151586610.1016/S0016-5085(98)70365-89649459
  58. S SaharaM SugimotoRK VilaichoneV MahachaiH MiyajimaT FurutaRole of Helicobacter pylori cagA EPIYA motif and vacA genotypes for the development of gastrointestinal diseases in Southeast Asian countries: a meta-analysisBMC Infect Dis20121222310.1186/1471-2334-12-22322994150
  59. M SugimotoY YamaokaThe association of vacA genotype and Helicobacter pylori-related disease in Latin American and African populationsClin Microbiol Infect200915983584210.1111/j.1469-0691.2009.02769.x19392900
  60. T OhnoA VallstromM RuggeH OtaDY GrahamA ArnqvistEffects of blood group antigen-binding adhesin expression during Helicobacter pylori infection of Mongolian gerbilsJ Infect Dis2011203572673510.1093/infdis/jiq09021227917
  61. H LuPI HsuDY GrahamY YamaokaDuodenal ulcer promoting gene of helicobacter pyloriGastroenterology2005128483384810.1053/j.gastro.2005.01.00915825067
  62. NR HusseinThe association of dupA and Helicobacter pylori-related gastroduodenal diseasesEur J Clin Microbiol Infect Dis201029781782110.1007/s10096-010-0933-z20419465
  63. S ShiotaO MatsunariM WatadaK HanadaY YamaokaSystematic review and meta-analysis: the relationship between the Helicobacter pylori dupA gene and clinical outcomesGut Pathog2010211310.1186/1757-4749-2-1321040520
  64. RH ArgentA BuretteVY Miendje DeyiJC AthertonThe presence of dupA in Helicobacter pylori is not significantly associated with duodenal ulceration in Belgium, South Africa, China, or North AmericaClin Infect Dis20074591204120610.1086/52217717918084
  65. YC YehHC ChengWL ChangHB YangBS SheuMatrix metalloproteinase-3 promoter polymorphisms but not dupA-H. pylori correlate to duodenal ulcers in H. pylori-infected femalesBMC Microbiol20101021810.1186/1471-2180-10-21820707923
  66. SW JungM SugimotoS ShiotaDY GrahamY YamaokaThe intact dupA cluster is a more reliable Helicobacter pylori virulence marker than dupA aloneInfect Immun201280138138710.1128/IAI.05472-1122038914
  67. A Talebi Bezmin AbadiG Perez-PerezRole of dupA in virulence of helicobacter pyloriWorld J Gastroenterol20162246101181012310.3748/wjg.v22.i46.1011828028359
  68. RM Peek JrSA ThompsonJP DonahueKT ThamJC AthertonMJ BlaserAdherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcomeProc Assoc Am Physicians199811065315449824536
  69. SM SheuBS SheuHB YangC LiTC ChuJJ WuPresence of iceA1 but not cagA, cagC, cagE, cagF, cagN, cagT, or orf13 genes of Helicobacter pylori is associated with more severe gastric inflammation in TaiwaneseJ Formos Med Assoc20021011182311911033
  70. S ShiotaM WatadaO MatsunariS IwataniR SuzukiY YamaokaHelicobacter pylori iceA, clinical outcomes, and correlation with cagA: a meta-analysisPLoS One201271e3035410.1371/journal.pone.003035422279585
  71. Y YamaokaDH KwonDY GrahamA M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pyloriProc Natl Acad Sci U S A200097137533753810.1073/pnas.13007979710852959
  72. Y YamaokaS KikuchiHM el-ZimaityO GutierrezMS OsatoDY GrahamImportance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 productionGastroenterology2002123241442410.1053/gast.2002.3478112145793
  73. A DossumbekovaC PrinzJ MagesR LangJG KustersAH VlietHelicobacter pylori HopH (OipA) and bacterial pathogenicity: genetic and functional genomic analysis of hopH gene polymorphismsJ Infect Dis2006194101346135510.1086/50842617054063
  74. J LiuC HeM ChenZ WangC XingY YuanAssociation of presence/absence and on/off patterns of Helicobacter pylori oipA gene with peptic ulcer disease and gastric cancer risks: a meta-analysisBMC Infect Dis20131355510.1186/1471-2334-13-55524256489
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6131906/fullTextXML. The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as Helicobacter pylori infectious disease.